Aspirin for Primary Prevention of Cardiovascular Disease

Overall Recommendations

• Routine use of low‑dose aspirin for primary prevention in most adults is not recommended because contemporary high‑quality evidence shows that bleeding risk equals or exceeds cardiovascular benefit in the setting of optimized statin and blood‑pressure therapy. ACC/AHA (Class IIb) 1
• The 2019 ACC/AHA guideline downgraded aspirin to a Class IIb recommendation (may be considered) for primary prevention, reflecting a shift based on three landmark 2018 trials (ASCEND, ARRIVE, ASPREE) that together enrolled >46 000 participants and demonstrated that modest cardiovascular benefit was offset by increased bleeding risk. ACC/AHA (moderate‑to‑high evidence) 1
• In unselected populations, the number needed to treat (NNT) to cause a major bleed (210) is lower than the NNT to prevent an ASCVD event (265), indicating net harm. ACC/AHA (high‑quality meta‑analysis) 1

Age‑Based Recommendations

• Adults 40–59 years with ≥10 % 10‑year ASCVD risk – low‑dose aspirin (75–100 mg daily) may be considered only in highly selected patients who meet all of the following: age 40–59, calculated 10‑year ASCVD risk ≥10 %, low bleeding risk, willingness for lifelong therapy, and at least one additional high‑risk feature (e.g., current smoking, strong family history of premature ASCVD, inadequately controlled cholesterol, coronary calcium score ≥100, chronic kidney disease/albuminuria). ACC/AHA (conditional recommendation) 1
• Shared decision‑making is essential to weigh the small cardiovascular benefit against a comparable bleeding risk. Diabetes Care (moderate certainty) 2
• Adults 60–70 years – aspirin should generally not be initiated for primary prevention; the USPSTF 2022 statement concludes with moderate certainty that there is no net benefit (Grade D). USPSTF (moderate certainty, Grade D) 2
• Adults >70 years – aspirin should not be used for primary prevention; the ASPREE trial showed increased bleeding and mortality without cardiovascular benefit, and extended follow‑up reported higher major adverse cardiovascular events (HR 1.17) and persistent bleeding risk (HR 1.24). ACC/AHA (high‑quality trial data) 1

Absolute Contraindications to Aspirin (Primary Prevention)

• Prior gastrointestinal bleeding or active peptic ulcer disease
• Known bleeding disorder or thrombocytopenia
• Severe liver disease
• Concurrent anticoagulation (warfarin or DOACs)
• Regular NSAID use
• Uncontrolled hypertension (elevated blood pressure) Diabetes Care (moderate evidence) 2
• Chronic kidney disease (increases bleeding risk)
• Age > 70 years ACC/AHA (high‑quality evidence) 1

Special Population: Diabetes

• Aspirin is not routinely recommended for primary prevention in patients with diabetes; the ASCEND trial (15 480 diabetic participants without prior ASCVD) showed a 12 % relative reduction in serious vascular events (8.5 % vs 9.6 %) but a 29 % relative increase in major bleeding (4.1 % vs 3.2 %). Diabetes Care (high‑quality RCT) 2
• For diabetic individuals ≥50 years with at least one additional major cardiovascular risk factor (family history of premature ASCVD, hypertension, dyslipidemia, smoking, or chronic kidney disease), aspirin may be considered only after shared decision‑making and if bleeding risk is low. Diabetes Care (moderate certainty) 2

Secondary Prevention (Strong Indication)

• Aspirin 75–162 mg daily (most commonly 81 mg in the U.S.) remains strongly recommended for all patients with established ASCVD, where the benefit substantially outweighs bleeding risk. Diabetes Care (strong recommendation) 2

Rationale for the Paradigm Shift

• Modern populations have lower smoking rates, widespread statin use (34–75 % in recent trials versus minimal use in older studies), and improved blood‑pressure control Diabetes Care (moderate evidence) 2; these factors lower baseline cardiovascular risk, making aspirin’s absolute benefit smaller while bleeding risk remains unchanged. ACC/AHA (high‑quality evidence) 1

Practical Dosing When Aspirin Is Used After Risk‑Benefit Assessment

• Use low‑dose aspirin 75–100 mg daily (81 mg standard U.S. tablet). Diabetes Care (moderate evidence) 2
• No evidence supports doses >162 mg for primary prevention. Diabetes Care (moderate evidence) 2
• Enteric‑coated formulations have not demonstrated a clear reduction in gastrointestinal bleeding risk. Diabetes Care (moderate evidence) 2

Clinical Pitfalls to Avoid

• Do not prescribe aspirin automatically based solely on a 10 % 10‑year ASCVD risk threshold; contemporary trials show an unfavorable risk‑benefit ratio at this cutoff. ACC/AHA (high‑quality evidence) 1
• Gastrointestinal bleeding risk in real‑world settings may be as high as 5 per 1 000 person‑years; this risk must be incorporated into net‑benefit calculations. Diabetes Care (moderate evidence) 2

Aspirin for Primary Prevention in Elevated ASCVD Risk

Current Guideline Recommendations

• The American College of Cardiology and American Heart Association downgraded aspirin to a Class IIb recommendation for primary prevention, reflecting the unfavorable risk-benefit ratio in modern practice 3, 4
• The American College of Cardiology and American Heart Association recommend that low-dose aspirin might be considered only for highly select adults aged 40-70 years at higher ASCVD risk who are not at increased bleeding risk 3, 4
• The American College of Cardiology and American Heart Association recommend that aspirin should not be used routinely in adults over 70 years of age 3, 4
• The American College of Cardiology and American Heart Association recommend that aspirin should not be used in any adult at increased bleeding risk 3, 4

Why the Shift Away from Aspirin?

• Recent large trials demonstrate that aspirin's modest cardiovascular benefit is offset by comparable bleeding risk when patients receive contemporary evidence-based therapies 5, 6
• The ASCEND trial showed only a 12% reduction in cardiovascular events, but a 29% increase in major bleeding 5
• The number of ASCVD events prevented equals the number of bleeding episodes induced in patients with over 1% annual ASCVD risk 5, 6

Specific Populations Where Aspirin Should Be Avoided

• Adults over 70 years have a greater bleeding risk than cardiovascular benefit regardless of ASCVD risk 3, 4, 5
• Aspirin is contraindicated in patients with a history of gastrointestinal bleeding or peptic ulcer disease, thrombocytopenia or coagulopathy, chronic kidney disease, or concurrent use of NSAIDs, steroids, anticoagulants, or other bleeding-risk medications 3, 4

When Aspirin IS Clearly Indicated: Secondary Prevention

• Aspirin remains strongly recommended for secondary prevention in patients with established ASCVD, where benefits far exceed risks 5, 6, 7
• The American Diabetes Association recommends aspirin for secondary prevention in patients with established ASCVD 7

Special Consideration: Diabetes

• The American Diabetes Association states that aspirin is not generally recommended for primary prevention in diabetic patients 6, 7
• Aspirin may be considered only in the context of shared decision-making for diabetic patients at high cardiovascular risk with low bleeding risk 7

Common Pitfalls to Avoid

• The 10% 10-year ASCVD risk threshold should not be used as an automatic indication for aspirin 3, 4
• Bleeding risk factors should not be overlooked when calculating net benefit 3, 4
• Aspirin should not be continued in patients over 70 years without documented ASCVD 3, 5

Aspirin Primary Prevention Guided by Coronary Artery Calcium (CAC) Score

Eligibility & Age Considerations

Bleeding‑Risk Contraindications

CAC‑Based Decision Algorithm

Risk Estimation Accuracy

Guideline Endorsements

Shared Decision‑Making Highlights

Practical Recommendations

Aspirin for Primary Prevention: Evidence‑Based Guidance

1. Criteria for Considering Low‑Dose Aspirin

• Current smoking is identified as a high‑risk feature that, together with age 40‑59 years, ≥10 % 10‑year ASCVD risk, low bleeding risk, and willingness for lifelong therapy, may justify aspirin use in primary prevention. 13
• In individuals aged 40‑59 years with a 10‑year ASCVD risk ≥ 10 % and who meet all of the following: low bleeding risk, willingness for lifelong therapy, and at least one additional high‑risk factor (e.g., current smoking, CAC ≥ 100, markedly elevated lipoprotein(a)), shared decision‑making is recommended because the net benefit is modest (≈1 event prevented per 100 patients treated over 5‑10 years, balanced by ≈1 major bleed). 14

2. Coronary Artery Calcium (CAC) Scoring as a Decision Tool

• The ACC/AHA, ESC, and NLA societies endorse CAC scoring as the preferred method to refine aspirin decisions when ASCVD risk estimation is uncertain. 14
• CAC = 0: Aspirin is not recommended because the near‑term cardiovascular event risk is very low. 14
• CAC ≥ 100: Aspirin (75‑100 mg daily) may be considered after shared decision‑making, as this level reflects substantial coronary plaque burden and shifts the benefit‑to‑harm ratio toward benefit. 14
• CAC 1‑99: Evidence is mixed; aspirin is generally not recommended unless multiple additional high‑risk features are present. 14

3. Absolute Contraindications to Aspirin

• Severe liver disease constitutes an absolute contraindication to aspirin therapy. 15

4. Lipid Management (Statin‑First Strategy)

• Adults with elevated cholesterol who have ≥ 2 cardiovascular risk factors should receive a maximally tolerated high‑potency statin (e.g., atorvastatin, rosuvastatin, or pitavastatin) with a target LDL‑C < 100 mg/dL (2.6 mmol/L). 13
• If the LDL‑C goal is not achieved after 12 weeks of lifestyle modification and statin therapy, addition of ezetimibe and/or bempedoic acid is recommended. 15
• Recommended lifestyle measures include limiting saturated fat to < 7 % of total calories, dietary cholesterol < 200 mg/day, consuming 10‑25 g/day of viscous fiber, up to 2 g/day of plant sterols/stanols, weight reduction, and ≥ 30 minutes of moderate‑intensity physical activity on most days. 13

5. Diabetes‑Specific Recommendations

• Routine aspirin for primary prevention in patients with diabetes is not recommended; the ASCEND trial (15,480 diabetic participants) showed only a 12 % relative reduction in serious vascular events (8.5 % vs 9.6 %) but a 29 % relative increase in major bleeding (4.1 % vs 3.2 %). 16
• Aspirin may be considered in diabetic adults ≥ 50 years who have at least one additional major cardiovascular risk factor (e.g., family history of premature ASCVD, hypertension, dyslipidemia, smoking, or chronic kidney disease) and have low bleeding risk, after shared decision‑making. 16

6. Familial Hypercholesterolemia (FH) Considerations

• In asymptomatic FH patients at higher ASCVD risk (e.g., markedly elevated lipoprotein(a), coexisting diabetes, or adverse cardiovascular imaging findings), low‑dose aspirin may be considered for primary prevention provided there are no bleeding contraindications. 15

Coronary Artery Calcium–Guided Aspirin Initiation for Primary Prevention

CAC Threshold for Starting Aspirin

• In adults with low‑to‑moderate bleeding risk and an estimated 10‑year ASCVD risk of ≈5 %, low‑dose aspirin should be initiated when the coronary artery calcium (CAC) score is ≥ 100. 17, 18, 19
• Low‑dose aspirin (75–100 mg daily, typically 81 mg in the United States) is considered reasonable for patients with CAC ≥ 100 who also have low bleeding risk. 17, 18, 19

Higher CAC Scores

• For individuals with CAC > 400, the net clinical benefit of aspirin is even greater; aspirin improves outcomes regardless of traditional risk‑factor levels. 17, 19

Situations Where Aspirin Is Not Recommended

• When CAC = 0, aspirin is not recommended even if the calculated ASCVD risk is moderate (≈5 %), because the bleeding risk outweighs any cardiovascular benefit. 17, 19
• The only rare exception to the above is a CAC = 0 combined with a >20 % 10‑year ASCVD risk; in such cases aspirin may be considered. 17, 19

Guideline Endorsements

• Major international guideline bodies—including the American College of Cardiology/American Heart Association (ACC/AHA), the Society of Cardiovascular Computed Tomography (SCCT), the National Lipid Association (NLA), the Cardiac Society of Australia and New Zealand (CSANZ), and Chinese cardiovascular societies—explicitly endorse CAC ≥ 100 as the threshold at which aspirin’s cardiovascular benefit exceeds its bleeding risk. This reflects a high‑level consensus recommendation (2023). 17, 18, 19

Evidence Supporting the CAC ≥ 100 Threshold

• Observational cohort evidence: Multiple high‑quality cohort studies (e.g., Multi‑Ethnic Study of Atherosclerosis) demonstrate a graded increase in cardiovascular events with higher CAC scores, supporting the use of CAC ≥ 100 to identify patients who may benefit from aspirin. (Observational evidence) 17
• Meta‑analytic data: Meta‑analyses show that CAC ≥ 100 reliably identifies individuals in whom aspirin’s cardiovascular benefit outweighs bleeding risk, whereas CAC = 0 identifies those who would experience net harm from aspirin. (Meta‑analysis level evidence) 17
• Guideline consensus: Formal endorsement by the ACC/AHA, SCCT, NLA, CSANZ, and Chinese guideline committees (2023) provides authoritative, guideline‑level support for the CAC ≥ 100 threshold. (Guideline consensus) 17, 18, 19

Aspirin Use for Primary Prevention Guided by Coronary Calcium Score

Indications Based on CAC Score

• Adults aged 40–70 years with a coronary artery calcium (CAC) score > 100 should be offered low‑dose aspirin (75–100 mg daily) after shared decision‑making, because this threshold identifies a population in which cardiovascular benefit outweighs bleeding risk. 20

• International guideline bodies—including the ACC/AHA, Society of Cardiovascular Computed Tomography, National Lipid Association, Cardiac Society of Australia & New Zealand, and Chinese cardiovascular societies—explicitly endorse CAC ≥ 100 as the point at which aspirin’s cardiovascular benefit exceeds its bleeding risk. [Class IIb recommendation; expert consensus] 20

• When CAC > 400, the net clinical benefit of aspirin is even greater; aspirin improves outcomes irrespective of traditional risk‑factor levels. 20

• When CAC = 0, aspirin is not recommended even if the calculated 10‑year ASCVD risk is moderate, because bleeding risk outweighs any cardiovascular benefit. 20

• A rare exception: if CAC = 0 but the 10‑year ASCVD risk exceeds 20 %, aspirin may be considered after individualized risk‑benefit discussion. 20

Age‑Related Recommendations

• For individuals 40–70 years old, low‑dose aspirin may be considered only when CAC ≥ 100 and the patient has a low bleeding risk. 21

• The 2019 ACC/AHA guideline gives this a Class IIb recommendation (may be considered) for adults 40–70 years at higher ASCVD risk without increased bleeding risk. 21

• Aspirin should not be initiated for primary prevention in persons > 70 years, regardless of ASCVD risk or CAC score, because bleeding risk outweighs cardiovascular benefit. 22

• The ASPREE randomized trial in adults > 70 years showed increased major bleeding and all‑cause mortality without cardiovascular benefit; extended follow‑up reported a higher hazard for major adverse cardiovascular events (HR 1.17) and persistent bleeding risk (HR 1.24). [Level A evidence; RCT] 22

CAC Versus Traditional Risk Scores

• Coronary calcium scoring directly visualizes plaque burden and provides more accurate risk stratification than the pooled‑cohort equations, which tend to overestimate ASCVD risk in contemporary, statin‑treated populations. 20

• Higher CAC categories are independently associated with both ASCVD events and bleeding, but the association with ASCVD is stronger and remains significant after multivariable adjustment. 20

• Do not rely on traditional risk scores alone when CAC testing is available; CAC ≥ 100 identifies a subgroup with net cardiovascular benefit that would be missed by risk‑score‑only approaches. 20

Evidence Supporting the Recommendations

• International guideline endorsement of CAC ≥ 100 (ACC/AHA, SCCT, NLA, CSANZ, Chinese societies) reflects expert consensus that the benefit‑to‑harm balance is favorable at this threshold. 20

• Randomized evidence from the ASPREE trial demonstrates net harm of aspirin in adults > 70 years, underpinning the age‑restriction recommendation. 22

• Observational and modeling data indicate a 5‑year number needed to treat (NNT) of ≈ 140 to prevent one ASCVD event versus a number needed to harm (NNH) of ≈ 518 for major bleeding when CAC ≥ 100, supporting a net benefit. 20 (derived from cited sources)

• When CAC = 0, the 5‑year NNT rises to ≈ 1,190 while the NNH is ≈ 567, indicating net harm and justifying avoidance of aspirin. 20 (derived from cited sources)